Clinical impact of a drug information service provided by a pharmacovigilance centre in a French University Hospital
- 1Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Univ Toulouse, CHU Toulouse, Toulouse, France
Abstract
Purpose: Pharmacovigilance Centres (PVCs) provide independent drug information to healthcare professionals in addition to their pharmacovigilance activities. However, their impact on clinical decision-making has been poorly studied. This study assessed the impact of a French PVC on clinical management in a tertiary university hospital (Toulouse University Hospital).
Methods: We conducted a retrospective observational study including all drug-related enquiries submitted to the Toulouse PVC during 2024. Impact was evaluated according to three predefined criteria: whether the enquiry was submitted before or after a clinical management decision had been made, concordance between PVC recommendations and subsequent clinical management, and documentation of the advice in the electronic patient record. Based on these criteria, impact was classified as certain, probable, or uncertain for enquiries submitted before clinical management, and as confirmatory (validating an already implemented decision) or uncertain for enquiries submitted after clinical management had already been initiated.
Results: A total of 128 enquiries were analysed. Most concerned adverse drug reactions (111/128), involved hospitalised patients (100/128), and originated from a broad range of clinical departments, mainly geriatrics (14/128), gastroenterology (11/128), neurology (11/128), infectious diseases (10/128) and internal medicine (10/128). Overall, clinical management was concordant with PVC recommendations in 87% of cases. Among the 92 pre-decision enquiries, PVC impact was classified as certain in 62% and probable in 24% of cases. Among the 36 post-decision enquiries, PVC advice was confirmatory in 44% of cases. The enquiries also generated 50 pharmacovigilance reports, including one potential safety signal.
Conclusion: PVCs support both clinical decision-making and drug safety surveillance.
Related
- Clinical Characteristics of Cerebral Venous Thrombosis: A Descriptive Study from Minia University Hospital
- Serum Tumor Markers: Comparison between Guidelines and the Clinical Practice in a University Hospital Center
- Appropriateness of antibiotic prescribing in dental practice: results of two clinical audits conducted at a university hospital
- Barriers and facilitators to translating infection prevention knowledge into clinical practice at Bule Hora University Teaching Hospital, Ethiopia: mixed-methods study
- Postnatal Hypertension Management and Discharge Documentation: A Retrospective Clinical Audit at a UK University Hospital.
BibTeX
@article{barus2026clinical,
title = {{Clinical impact of a drug information service provided by a pharmacovigilance centre in a French University Hospital}},
author = {Romain Barus and Anthony Foch and Pauline Schiro and François Montastruc and Haleh Bagheri and Claire de Canecaude},
journal = {European Journal of Clinical Pharmacology},
year = {2026},
month = oct,
doi = {10.1007/s00228-026-04207-3},
url = {https://doi.org/10.1007/s00228-026-04207-3},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Clinical impact of a drug information service provided by a pharmacovigilance centre in a French University Hospital
AU - Romain Barus
AU - Anthony Foch
AU - Pauline Schiro
AU - François Montastruc
AU - Haleh Bagheri
AU - Claire de Canecaude
PY - 2026
DA - 2026/10/28
JO - European Journal of Clinical Pharmacology
DO - 10.1007/s00228-026-04207-3
UR - https://doi.org/10.1007/s00228-026-04207-3
AB - Purpose: Pharmacovigilance Centres (PVCs) provide independent drug information to healthcare professionals in addition to their pharmacovigilance activities. However, their impact on clinical decision-making has been poorly studied. This study assessed the impact of a French PVC on clinical management in a tertiary university hospital (Toulouse University Hospital). Methods: We conducted a retrospective observational study including all drug-related enquiries submitted to the Toulouse PVC during 2024. Impact was evaluated according to three predefined criteria: whether the enquiry was submitted before or after a clinical management decision had been made, concordance between PVC recommendations and subsequent clinical management, and documentation of the advice in the electronic patient record. Based on these criteria, impact was classified as certain, probable, or uncertain for enquiries submitted before clinical management, and as confirmatory (validating an already implemented decision) or uncertain for enquiries submitted after clinical management had already been initiated. Results: A total of 128 enquiries were analysed. Most concerned adverse drug reactions (111/128), involved hospitalised patients (100/128), and originated from a broad range of clinical departments, mainly geriatrics (14/128), gastroenterology (11/128), neurology (11/128), infectious diseases (10/128) and internal medicine (10/128). Overall, clinical management was concordant with PVC recommendations in 87% of cases. Among the 92 pre-decision enquiries, PVC impact was classified as certain in 62% and probable in 24% of cases. Among the 36 post-decision enquiries, PVC advice was confirmatory in 44% of cases. The enquiries also generated 50 pharmacovigilance reports, including one potential safety signal. Conclusion: PVCs support both clinical decision-making and drug safety surveillance.
SN - 0031-6970
SN - 1432-1041
ER -